215 related articles for article (PubMed ID: 29044458)
21. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
[TBL] [Abstract][Full Text] [Related]
23. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
Rosenberg AJ; Agrawal N; Pearson A; Gooi Z; Blair E; Cursio J; Juloori A; Ginat D; Howard A; Chin J; Kochanny S; Foster C; Cipriani N; Lingen M; Izumchenko E; Seiwert TY; Haraf D; Vokes EE
Oral Oncol; 2021 Nov; 122():105566. PubMed ID: 34662771
[TBL] [Abstract][Full Text] [Related]
24. Quality of life in advanced oropharyngeal carcinoma after chemoradiation versus surgery and radiation.
Mowry SE; Ho A; Lotempio MM; Sadeghi A; Blackwell KE; Wang MB
Laryngoscope; 2006 Sep; 116(9):1589-93. PubMed ID: 16954985
[TBL] [Abstract][Full Text] [Related]
25. Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality.
Maxwell JH; Mehta V; Wang H; Cunningham D; Duvvuri U; Kim S; Johnson JT; Ferris RL
Laryngoscope; 2014 Jul; 124(7):1592-7. PubMed ID: 24353066
[TBL] [Abstract][Full Text] [Related]
26. Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.
Vainshtein JM; Moon DH; Feng FY; Chepeha DB; Eisbruch A; Stenmark MH
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):925-33. PubMed ID: 25832685
[TBL] [Abstract][Full Text] [Related]
27. Quality of life outcomes of transoral robotic surgery with or without adjuvant therapy for oropharyngeal cancer.
Sethia R; Yumusakhuylu AC; Ozbay I; Diavolitsis V; Brown NV; Zhao S; Wei L; Old M; Agrawal A; Teknos TN; Ozer E
Laryngoscope; 2018 Feb; 128(2):403-411. PubMed ID: 28771728
[TBL] [Abstract][Full Text] [Related]
28. Practice patterns and outcomes following radiation dose de-escalation for oropharyngeal cancer.
White R; Abel S; Hasan S; Verma V; Greenberg L; Colonias A; Wegner RE
Laryngoscope; 2020 Apr; 130(4):E171-E176. PubMed ID: 31120601
[TBL] [Abstract][Full Text] [Related]
29. Long-term quality of life in older patients with HPV-related oropharyngeal cancer.
Baxi SS; Cullen G; Xiao H; Atoria CL; Sherman EJ; Ho A; Lee NY; Elkin EB; Pfister DG
Head Neck; 2018 Nov; 40(11):2321-2328. PubMed ID: 30421835
[TBL] [Abstract][Full Text] [Related]
30. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Loong HH; Winquist E; Waldron J; Chen EX; Kim J; Palma D; Read N; Razak AR; Diaz-Padilla I; Chan K; Bayley A; Hossain M; Wang L; Chin S; Siu LL; Hope A
Eur J Cancer; 2014 Sep; 50(13):2263-70. PubMed ID: 24953566
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.
Lorch JH; Hanna GJ; Posner MR; O'Neill A; Thotakura VL; Limaye SA; Rabinowits G; Sher DJ; Tishler RB; Haddad RI
Head Neck; 2016 Apr; 38 Suppl 1():E1618-24. PubMed ID: 26614576
[TBL] [Abstract][Full Text] [Related]
32. Quality of life in survivors of oropharyngeal cancer: A systematic review and meta-analysis of 1366 patients.
Høxbroe Michaelsen S; Grønhøj C; Høxbroe Michaelsen J; Friborg J; von Buchwald C
Eur J Cancer; 2017 Jun; 78():91-102. PubMed ID: 28431302
[TBL] [Abstract][Full Text] [Related]
33. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
34. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial.
Machtay M; Rosenthal DI; Hershock D; Jones H; Williamson S; Greenberg MJ; Weinstein GS; Aviles VM; Chalian AA; Weber RS;
J Clin Oncol; 2002 Oct; 20(19):3964-71. PubMed ID: 12351593
[TBL] [Abstract][Full Text] [Related]
35. Impact of post-chemoradiotherapy superselective/selective neck dissection on patient reported quality of life.
Wang K; Amdur RJ; Mendenhall WM; Green R; Aumer S; Hackman TG; Zanation AM; Zevallos JP; Patel SN; Weissler MC; Chera BS
Oral Oncol; 2016 Jul; 58():21-6. PubMed ID: 27311398
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI.
Rinkel RN; Verdonck-de Leeuw IM; Doornaert P; Buter J; de Bree R; Langendijk JA; Aaronson NK; Leemans CR
Eur Arch Otorhinolaryngol; 2016 Jul; 273(7):1849-55. PubMed ID: 26071622
[TBL] [Abstract][Full Text] [Related]
37. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.
Xiao C; Zhang Q; Nguyen-Tân PF; List M; Weber RS; Ang KK; Rosenthal D; Filion EJ; Kim H; Silverman C; Raben A; Galloway T; Fortin A; Gore E; Winquist E; Jones CU; Robinson W; Raben D; Le QT; Bruner D
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):667-677. PubMed ID: 27727063
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.
Cmelak AJ; Li S; Goldwasser MA; Murphy B; Cannon M; Pinto H; Rosenthal DI; Gillison M; Forastiere AA
J Clin Oncol; 2007 Sep; 25(25):3971-7. PubMed ID: 17761982
[TBL] [Abstract][Full Text] [Related]
39. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
40. Shoulder symptoms and quality of life impact of limited neck dissection after de-intensified chemoradiotherapy: Secondary analysis of two prospective trials.
Wang K; Moon DH; Amdur RJ; Dagan R; Sheets NC; Shen CJ; Green R; Patel SN; Zanation AM; Thorp BD; Hackman TG; Weissler MC; Mendenhall WM; Chera BS
Head Neck; 2019 May; 41(5):1213-1219. PubMed ID: 30554453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
